Related Experiment Video
Updated: Mar 30, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Medical therapy, percutaneous coronary intervention and prognosis in patients with chronic total occlusions
Andrew Ladwiniec1, Victoria Allgar2, Simon Thackray3
1Department of Cardiology, Castle Hill Hospital, Kingston-upon-Hull, UK Department of Health Sciences, Hull York Medical School, York, UK.
Insights
Revascularization for chronic total coronary occlusion (CTO) improves long-term survival compared to medical therapy alone. Percutaneous coronary intervention (PCI) for CTO shows a trend towards better outcomes, but any revascularization is key.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Outcomes Research
Background:
- Limited data exists comparing outcomes of medical therapy versus percutaneous coronary intervention (PCI) for chronic total coronary occlusion (CTO).
- Understanding long-term clinical outcomes is crucial for managing patients with CTO.
Purpose of the Study:
- To compare long-term clinical outcomes between patients with CTO treated by PCI and those treated with elective medical therapy.
- To evaluate the effectiveness of revascularization strategies for CTO.
Main Methods:
- A consecutive cohort of 1957 patients with CTO identified between 2002-2007 was analyzed.
- Propensity score matching created 294 pairs comparing CTO PCI and medical therapy.
- Long-term clinical outcomes, including all-cause mortality and myocardial infarction, were assessed at 5 years.
Main Results:
- PCI was successful in 60.2% of CTO cases.
- Five-year all-cause mortality was lower in the CTO PCI group (11.6%) compared to medical therapy (16.7%).
- The composite of 5-year death or myocardial infarction was significantly lower with CTO PCI (13.9%) versus medical therapy (19.6%).
Conclusions:
- Revascularization of CTO, regardless of method, is associated with improved long-term survival compared to medical therapy alone.
- While PCI for CTO shows a trend towards better outcomes, the primary benefit lies in achieving revascularization.
Objective:
There is little published data reporting outcomes for those found to have a chronic total coronary occlusion (CTO) that is electively treated medically versus those treated by percutaneous coronary intervention (PCI). We sought to compare long-term clinical outcomes between patients treated by PCI and elective medical therapy in a consecutive cohort of patients with an identified CTO.
Methods:
Patients found to have a CTO on angiography between January 2002 and December 2007 in a single tertiary centre were identified using a dedicated database. Those undergoing CTO PCI and elective medical therapy to the CTO were propensity matched to adjust for baseline clinical and angiographic differences.
Results:
In total, 1957 patients were identified, a CTO was treated by PCI in 405 (20.7%) and medical therapy in 667 (34.1%), 885 (45.2%) patients underwent coronary artery bypass graft surgery. Of those treated by PCI or medical therapy, propensity score matching identified 294 pairs of patients, PCI was successful in 177 patients (60.2%). All-cause mortality at 5 years was 11.6% for CTO PCI and 16.7% for medical therapy HR 0.63 (0.40 to 1.00, p=0.052). The composite of 5-year death or myocardial infarction occurred in 13.9% of the CTO PCI group and 19.6% in the medical therapy group, HR 0.64 (0.42 to 0.99, p=0.043). Among the CTO PCI group, if the CTO was revascularised by any means during the study period, 5-year mortality was 10.6% compared with 18.3% in those not revascularised in the medical therapy group, HR 0.50 (0.28-0.88, p=0.016).
Conclusions:
Revascularisation, but not necessarily PCI of a CTO, is associated with improved long-term survival relative to medical therapy alone.
More Related Videos
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Angina IV: Management
Atherosclerosis III: Management
Cardiomyopathy V: Interprofessional Care

